| Document |
Document Title |
|
WO/2000/029357A1 |
The invention relates to a method for the racemization of optically active amines by reacting an optically active amine in the presence of hydrogen with a hydrogenation or dehydrogenation catalyst at an elevated temperature, wherein said...
|
|
WO/2000/027790A1 |
A compound of formula (IA) or (IB): in which R?1¿ is R?A¿(CH¿2?)¿n?O(CH¿2?)¿m?, R?A¿(CH¿2?)¿p?, Formula (II) or in which R is a spiro-fused mono- or bi-cyclic ring containing one or two basic nitrogen atoms; and X?1¿ and X?2¿,...
|
|
WO/2000/027795A1 |
Disclosed are compounds capable of facilitating transport of biologically active agents or substances into cells having general structure (A).
|
|
WO/2000/027796A1 |
The invention concerns a method for preparing tris(ether-amines) of formula (I): N[A-O-(B-O)¿n?-R]¿3? wherein R, A, B and n are as defined in Claim 1, comprising the reaction, in liquid phase, of an alkylene-glycol monoether of formula...
|
|
WO/2000/026167A1 |
The invention concerns novel bi-aromatic compounds of general formula (I) and the method for preparing them, and their use in pharmaceutical compositions for use in human or veterinary medicine (in dermatology, in cancerology, and in the...
|
|
WO/2000/025767A2 |
The use of a compound of Formula (VIII) in the manufacture of a medicament for the treatment of or the prevention of neurological disorders, in a warm-blooded mammal, wherein A and B are selected from: Formula (IX) or Formula (X) such th...
|
|
WO1999064038A9 |
Novel multibinding compounds are disclosed. The compounds of the invention comprise from 2-10 ligands covalently connected, each of said ligands being capable of binding to an nAChR receptor, thereby modulating the biological processes/f...
|
|
WO1999064031A9 |
The present invention is directed to multibinding compounds which are beta 2-adrenergic receptor agonists and are therefore useful in the treatment and prevention of respiratory diseases such as asthma, bronchitis, and the like. They are...
|
|
WO/2000/024697A1 |
Aldehyde derivatives of polyethylene glycols and methods of making thereof are disclosed. These aldehyde derivatives can be used to make polyethylene glycol-hydrazines, polyethylene glycol-thiols, polyethylene glycol amines, and branched...
|
|
WO/2000/023417A1 |
The present invention relates to compounds of general formula (Ia). The compounds are useful in the treatment and/or prevention of conditions mediated by nuclear receptors, in particular the Peroxisome Proliferator-Activated Receptors (P...
|
|
WO/2000/023416A1 |
The present invention relates to compounds of general formula (Ia). The compounds are useful in the treatment and/or prevention of conditions mediated by nuclear receptors, in particular the Peroxisome Proliferator-Activated Receptors (P...
|
|
WO1999063933A9 |
Disclosed are multibinding compounds which are agonists, partial agonists, inverse agonists, partial inverse agonist or antagonists of the GABA receptors, which are involved in neurological disorders. The multibinding compounds of this i...
|
|
WO/2000/021917A1 |
The invention relates to N,N-dimethyl-{3-phenyl-3-[(4-trifluoromethyl)-phenoxy]-propy
l-amine}-p-toluenesulfonate of Formula (I) and an improved process for the preparation thereof. The new compound of Formula (I) is a valuable pharmaceu...
|
|
WO1999064000A9 |
Novel multi-binding compounds (agents) which bind neurokinin receptors are used to treat disorders in mammals that are mediated by the neurokinin receptors, such as Parkinson's disease, Alzheimer's disease, depression, anxiety, inflammat...
|
|
WO/2000/021910A2 |
Compounds of Formula (I), wherein the substituents are as described in the specification or pharmaceutically acceptable salts or stereochemically isomeric forms thereof, useful for treating diseases related to calcium imbalance and metab...
|
|
WO/2000/021487A2 |
A method is disclosed for the preparation of optically pure isomers of formoterol and polymorphs of the novel $i(L)-tartrate salt of $i(R,R)-formoterol. Pharmaceutical compositions of the polymorphs and salts are also described.
|
|
WO/2000/020377A1 |
New ligands having a backbone comprised of NCCX can be combined with a metal or metal precursor compound or formed into a metal-ligand complex to catalyze a number of different chemical transformations, including polymerization.
|
|
WO/2000/020376A1 |
$g(b)-Aminotetralin derivatives of formula (I) which are ligands for the neuropeptide Y Y5 (NPY5) receptor, methods of preparation and pharmaceutical compositions containing a $g(b)-aminotetralin derivative as the active ingredient are d...
|
|
WO/2000/018724A1 |
The invention relates to substituted aryl and heteroaryl (R)-Chiral Halogenated 1-Substitutedamino-(n+1)-Alkanol compounds useful as inhibitors of cholesteryl ester transfer protein (CETP; plasma lipid transfer protein-I) and compounds, ...
|
|
WO/2000/018722A2 |
The present invention relates to new derivatives of 6-(4-phenylbutoxy)hexylamine having the general formula (I) wherein R¿1? is CHO, or CHOR¿3?OR¿4?, wherein R¿3? and R¿4? are independently C¿1?-C¿6? alkyl, aralkyl or can form cyc...
|
|
WO/2000/018721A1 |
The invention relates to substituted polycyclic aryl and heteroaryl $i(tertiary)-heteroalkylamine compounds useful as inhibitors of cholesteryl ester transfer protein (CETP; plasma lipid transfer protein-I) and compounds, compositions an...
|
|
WO/2000/018723A1 |
The invention relates to substituted N-Aliphatic-N-Aromatic $i(tertiary)-Heteroalkylamine compounds useful as inhibitors of cholesteryl ester transfer protein (CETP; plasma lipid transfer protein-I) and compounds, compositions and method...
|
|
WO/2000/017152A1 |
Amine derivatives represented by general formula (1) and preparations for external use containing the same which exhibit excellent effects of preventing the skin from aging, etc. In formula (1), R?1¿ represents C¿1-30? hydrocarbyl opti...
|
|
WO/2000/017133A2 |
The invention concerns LTA¿4? hydrolase inhibiting compounds of formula (I). It also concerns their therapeutic, in particular anti-inflammatory, applications.
|
|
WO/2000/015614A1 |
The invention relates to novel pyridyl derivatives (I), their use as medicaments, pharmaceutical formulations including them and methods for their preparation.
|
|
WO1999063983A9 |
Disclosed are novel multi-binding compounds (agents) which bind to PPAR gamma receptors. The compounds of this invention comprise a plurality of ligands each of which can bind to such receptors thereby modulating the biological processes...
|
|
WO/2000/015601A1 |
Aliphatic primary alcohols, including aliphatic primary alcohols possessing one or more oxygen, nitrogen and/or phosphorus heteroatoms that may be atoms substituting for carbon atoms in the alkyl group or component atoms of substituents ...
|
|
WO/2000/014174A1 |
An organic electroluminescence device having a low driving voltage and a long life and a material having a small ionization potential and providing a large hole mobility when used as a layer or region are disclosed. The organic electrolu...
|
|
WO1999063932A9 |
Disclosed are multibinding compounds are capable of binding to a 5-HT cell membrane transporter. The multibinding compounds of this invention contain from 2 to 10 ligands covalently attached to one or more linkers. the mltibinding compou...
|
|
WO/2000/014173A1 |
The invention relates to an electroluminescent system consisting of a substrate, an anode, an electroluminescent element and a cathode. At least one of the two electrodes is transparent in the visual spectral range and the electrolumines...
|
|
WO/2000/012462A1 |
This invention relates to new aminoalcohol derivatives or salts thereof represented by formula (I) wherein each symbol is as defined in the specification or salts thereof which have $g(b)¿3? adrenergic agonist activity and therefore hav...
|
|
WO/2000/012461A1 |
This invention relates to a process for preparing 2-amino-5-cyanophenol.
|
|
WO/2000/012075A1 |
The present invention describes novel nitrosated and/or nitrosylated $g(a)-adrenergic receptor antagonists, and novel compositions containing at least one nitrosated and/or nitrosylated $g(a)-adrenergic receptor antagonist, and, optional...
|
|
WO/2000/011203A1 |
The invention relates to a method for the racemic cleavage of alkoxy-substituted primary amines by reaction with an ester in the presence of a lipase and subsequent separation of the resulting optically active amide from the optically ac...
|
|
WO1999064043A9 |
Disclosed are multibinding compounds which are muscarinic receptor antagonists. The multibinding compounds of this invention containing from 2 to 10 ligands covalently attached to one or more linkers. Each ligand is, independently of eac...
|
|
WO/2000/009472A1 |
N-Cyclopropyl-2-difluoromethoxy-3-halogenoanilines which serve as important intermediates in the preparation of quinolonecarboxylic acids useful as synthetic antimicrobial agents from industrially inexpensive and easily available raw mat...
|
|
WO/2000/007972A1 |
Novel glucocorticoid and thyroid receptor ligands as provided which have the general formula (I) in which: R¿1? is an aliphatic hydrocarbon, an aromatic hydrocarbon, carboxylic acid or ester thereof, alkenyl carboxylic acid or ester the...
|
|
WO/2000/007709A1 |
The present invention relates to surfactants useful in life science and industrial formulations. More particularly, the invention relates to surfactants of alkoxylated amine neutralized by aromatic sulfonic acid and pesticide formulation...
|
|
WO/2000/007976A1 |
A synthesis of fluoxetine is disclosed. The process begins with benzoylacetonitrile, which is reduced, optionally in the presence of a chiral ligand, to produce the corresponding aminoalcohol, and the amine is carbamoylated without isola...
|
|
WO/2000/007977A1 |
The invention relates to novel phenylethylamine derivatives, to a method for the production thereof and to their use as medicaments. The inventive phenylethylamines correspond to general formula (1).
|
|
WO/2000/006254A2 |
Use of a compound of formula (A), wherein: W is a residue which imparts antagonistic and/or agonistic activity at histamine H¿3?-receptors when attached to an imidazole ring in 4(5) position; R?1¿ and R?2¿ may be identical or differen...
|
|
WO/2000/006137A2 |
Compounds having Formula (I) are useful for modulating the glucocorticoid receptor in a mammal. Also disclosed are pharmaceutical compositions comprising compounds of Formula (I) and methods of treating immune, autoimmune, inflammatory, ...
|
|
WO/2000/006527A1 |
The 3- and 4-methylcatechols are converted to the corresponding benzaldehyde by first alkylating the hydroxyl groups to form an alkylated methylcatechol. The methyl group is then converted to a methyl dibromide group using 1,3-dibromo-5,...
|
|
WO/2000/006585A1 |
Nitric acid salts with medicines active in bony disorders.
|
|
WO/2000/005199A1 |
The present invention provides a process for the preparation of a wide range of primary arylamines. The arylamines are prepared in two efficient, straightforward transformations: 1) an activated aryl group and an imine group are combined...
|
|
WO/2000/005193A1 |
The present invention relates to novel guaiacoxypropanolamine derivatives of formula (I): wherein R is CH¿2?CH=CH¿2?, CH=CHCOOC¿2?H¿5?, CH=CHCH¿3?, CH¿2?NHCO(CH¿2?)¿7?CH¿3?; R¿3? is OH, OCH¿3?, NHCH¿2?CH¿3?OCH¿3?, CHR¿6?; ...
|
|
WO/2000/003979A1 |
The invention relates to novel benzocycloheptenes of general formula (I), wherein R?1¿, R?2¿ and SK have the meanings cited in the description. The novel compounds exhibit a selective estrogenic activity on bones and are suitable for p...
|
|
WO/2000/003975A2 |
The invention relates to aryl vinyl ether derivatives of general formula (I), wherein the substituents are as defined in the description; compositions containing them, processes and intermediates for their preparation and a method of con...
|
|
WO/2000/002839A1 |
A compound of formula (I), wherein $g(a)X is =O, =N-OR?6¿, $g(b)NHR or $g(b)OH wherein R?6¿ is H or C¿1?-C¿6? alkyl, bond a is oriented $g(g) or $g(d) and R is H, C¿1?-C¿6? alkyl which is unsubstituted or substituted by C¿6?-C¿10...
|
|
WO/2000/002846A1 |
Novel phenoxyacetic acid derivatives represented by general formula (I), and pharmacologically acceptable salts thereof, which exhibit an excellent $g(b)¿3?-adrenergic receptor stimulating effect and are useful as preventive or therapeu...
|
